Royal College of Surgeons of England Hunterian Professor (2020)
Consultant Hepatobiliary and Pancreatic Surgeon, University Department of Surgery, Addenbrooke’s Hospital
Honorary Clinician Scientist/Senior Research Fellow, MRC Cancer Unit
Email : firstname.lastname@example.org
Mr Liau is a Consultant Hepatopancreatobiliary Surgeon with a clinical interest in Advanced Minimally-invasive Hepatobiliary and Pancreatic Surgery. He was previously an MRC-Academy of Medical Sciences Clinician Scientist at the MRC Cancer Unit and University Department of Surgery, Addenbrooke’s Hospital, Cambridge. He was fellowship-trained in HPB Surgical Oncology and Abdominal Multiorgan Transplantation at the Toronto General Hospital, Canada and in Advanced Laparoscopic HPB Surgery at L’Institut Mutualiste Montsouris, Paris, France. He obtained a Doctorate of Medicine (MD) degree with Distinction from the University of Edinburgh and received surgical training in Cambridge, Toronto, Hong Kong, Paris and Edinburgh. He was also previously the International Hepatopancreatobiliary Association (IHPBA) Kenneth Warren Fellow at the Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, USA and the Cambridge University Parke-Davis Exchange Fellow with the University of Toronto, Canada.
Most recently, he was acknowledged by the Royal College of Surgeons of England with the award of the Hunterian Professorship. He was previously awarded the prestigious Association of Surgeons of Great Britain and Ireland (ASGBI) Moynihan Travelling Fellowship to Seoul, South Korea to focus on Robotic-assisted HPB surgery. In addition, he became the first UK surgeon to be awarded the Society of Surgery of Alimentary Tract (SSAT, USA) Karen and Josef Fischer International Travelling Fellowship.
His extensive international experience has allowed him to bring the best surgical practice to the UK NHS. He is a fond believer of evidence-based surgical practice for an optimal surgical outcome. His current clinical practice includes surgical management (minimally-invasive or open surgery) of HPB malignant and benign diseases. This include day-case laparoscopic cholecystectomies, and surgical management of complex gallstone diseases.
His current research interests has generated a personal research income of over £2.5 million and are focussed on the genetic evolution and therapy of pancreatic cancer and neoadjuvant clinical trials of novel therapeutics for pancreatic cancer. He also has a keen research interest in clinical and oncological outcome following HPB resections. The long-term goal is to use the research findings for personalised pancreatic cancer therapy.
Areas of expertise
HPB surgical oncology, pancreatic cancer, hepatobiliary cancer, minimally invasive surgery, day-case laparoscopic cholecystectomy, complex gallstone disease.